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BACKGROUND: Despite several years of research and attempts to develop prognostic models a considerable fraction of stage II colon
cancer patients will experience relapse within few years from their operation. The aim of the present study was to investigate the
prognostic importance of miRNA-21 (miR-21), quantified by in situ hybridisation, in a unique, large population-based cohort.
PATIENTS AND METHODS: The study included 764 patients diagnosed with stage II colon cancer in Denmark in the year 2003. One
section from a representative paraffin-embedded tumour tissue specimen from each patient was processed for analysis of miR-21
and quantitatively assessed by image analysis.
RESULTS: The miR-21 signal was predominantly observed in fibroblast-like cells located in the stromal compartment of the tumours.
We found that patients expressing high levels of miR-21 had significantly inferior recurrence-free cancer-specific survival (RF-CSS):
HR¼ 1.26; 95% CI: 1.15–1.60; Po0.001. In Cox regression analysis, a high level of miR-21 retained its prognostic importance and was
found to be significantly related to poor RF-CSS: HR¼ 1.41; 95% CI: 1.19–1.67; Po0.001.
CONCLUSION: The present study showed that increasing miR-21 expression levels were significantly correlated to decreasing RF-CSS.
Further investigations of the clinical importance of miR-21 in the selection of high-risk stage II colon cancer patients are merited.
British Journal of Cancer (2012) 107, 1169–1174. doi:10.1038/bjc.2012.365 www.bjcancer.com
& 2012 Cancer Research UK
Keywords: colon cancer; miRNA-21; population study; prognostic marker; stage II

















































Colon cancer represents a major challenge all over the Western
World (Parkin et al, 2005). The incidence has been increasing for
decades but screening holds the promise of a shift in distribution
towards earlier stages (Gross et al, 2006). Surgery is a cornerstone
in the treatment, but with operation alone a considerable fraction
of patients will experience tumour recurrence, calling for adjuvant
chemotherapy. Stage II (no lymph node metastases or distant
metastases) patients represent about 25% of all cases and they have
a 5-year overall survival (OS) of 73–85%, when surgically resected
(O’Connell, 2004).
There is a general agreement on postoperative chemotherapy for
stage III colon cancer patients, but there is still a debate on this
approach for patients with stage II tumours. Meta-analyses,
reviews and international guidelines agree that adjuvant
chemotherapy should be offered to a subgroup of patients with
high risk of recurrence, including T4 and T3 tumours with
lymphovascular invasion, high malignancy grade, perforation and/or
inadequate lymph node sampling (Benson III et al, 2004; Figueredo
et al, 2008; Kopetz et al, 2008; Bastos et al, 2010; Gangadhar and
Schilsky, 2010; Lombardi et al, 2010). Interestingly, the recent
CALBG 9581 study of 24 000 stage II patients from the Medicare
Registry found no improvement in 5-year survival in patients
receiving adjuvant chemotherapy, irrespective of a division of
patients into two groups with high- or low-risk characteristics
(O’Connor et al, 2011). These results question the current clinical
practice and underline the urgent need of new and reliable
prognostic and predictive markers in stage II colon cancer.
MicroRNAs (miRNAs) comprise an abundant class of endogen-
ous, small non-coding RNAs, 18–25 nucleotides in length, which
regulates protein synthesis at the post-transcriptional level.
MicroRNAs are highly conserved in sequence between distantly
related organisms, indicating their participation in essential
biological processes (Carrington and Ambros, 2003). Abnormal
expression of cancer-related miRNAs is characterised by increased
or decreased expression levels compared with their levels in the
corresponding normal tissue. The miRNA-21 (miR-21) is con-
sistently upregulated in many types of cancers including cancer of
the colon (Slaby et al, 2007; Schetter et al, 2008), breast (Yan et al,
2008; Qian et al, 2009), lung (Markou et al, 2008), stomach (Chan
et al, 2008) and glioblastoma (Gabriely et al, 2008). Among the
reported mRNA targets of miR-21 are PTEN, PDCD4, Spry-1 and
NF1B, suggesting that miR-21 is involved in regulation of
apoptosis, proliferation and migration (Meng et al, 2007;
Asangani et al, 2008; Gabriely et al, 2008; Yao et al, 2011).
Additionally, miR-21 levels seem to increase with increasing stage
of the tumour in, for example, colon and breast cancer, suggesting
an important role of miR-21 in cancer invasion and dissemination
(Slaby et al, 2007; Yan et al, 2008; Qian et al, 2009). These data
taken together strongly suggest miR-21 as a potential prognostic
marker in early-stage cancer such as stage II colon cancer. Studies
have found high levels of miR-21 in colorectal cancer patients to be
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an indicator of poor prognosis, but so far none have been
population based (Slaby et al, 2007; Schetter et al, 2008; Nielsen
et al, 2011).
Most studies quantifying miRNAs for identification of differ-
ential expression have been based on microarrays (Lim et al,
2005), real-time PCR (RT-PCR) (Bandres et al, 2006) and deep
sequencing (Ferdin et al, 2010). These quantitative miRNA
expression analysis platforms are strong quantitative tools with a
high level of precision and reproducibility and have been used to
identify valuable biomarker candidates. However, important
clinical information may be lost when focal miRNA expression is
masked by non-cancerous tissue present in the samples, such as
normal mucosa, submucosa and muscularis externa, mucous and
necrotic tissue (Bandres et al, 2006). Additionally, RNA extraction
from formalin-fixed paraffin-embedded (FFPE) tissue blocks is
both time-consuming and suboptimal. Current pathological
practice is based on FFPE tissue blocks, and the vast majority of
archival material is preserved as such. Therefore, new methods
should be considered. Recently, it has been reported that in situ
hybridisation (ISH) using locked nucleic acid (LNA) modified
DNA probes, raise the potential of evaluating tissue morphology
and to quantitatively assess the miR-21 signal (Nielsen et al, 2011;
Rask et al, 2011). The study by Nielsen et al also addressed the
prognostic information of miR-21 expression and found that high
miR-21 level was associated with poor disease-free survival.
However, the patient material was limited (Nielsen et al, 2011).
The aim of the present study was to further investigate the
prognostic importance of miR-21, quantified by ISH, in a unique,
large, homogeneous, population-based cohort consisting of all
patients with stage II colon cancer diagnosed and treated
exclusively by surgical resection in Denmark in the year 2003.
PATIENTS AND METHODS
Patients
The study population was retrieved by a search in the nationwide
registry administered by the Danish Colorectal Cancer Group
(DCCG). This database contains prospectively collected surgical
and pathological data. The search identified all surgically treated
patients diagnosed with stage II colon cancer in 2003 (N¼ 764).
Patients dying within 30 days from their operation were excluded
(N¼ 66). All but two hospitals participated in the study and hence
patients from those hospitals were not included (N¼ 56), thus
creating a highly representative cohort (93%) of the Danish
population of stage II colon cancer patients in 2003. Furthermore,
there were the following exclusions: tumour samples missing in
archives (N¼ 23); patients being categorised wrongly as stage II
colon cancer (N¼ 14); patients receiving adjuvant chemotherapy
(N¼ 16); lack of sufficient tissue for analysis (N¼ 7); analysis
exclusion criteria regarding number of images acquired o8
(N¼ 41) and TR values o20 000 (N¼ 21), see below. Thus, 520
patients were included in the statistical analysis. The study was
approved by the Regional Scientific Ethical Committee of Southern
Denmark according to Danish law. Postoperatively, patients were
followed by the treating departments according to local guidelines.
The patients were not routinely referred to a Department of
Oncology. Thus, the majority of data on recurrence and death were
obtained through Danish registries linked to the Danish social
security number given to every Danish citizen at birth and to all
ethnic immigrants.
The national registry holding all pathology reports in Denmark
was used to identify patients with pathologically verified
recurrence. Patients experiencing other malignancies were also
identified using this registry and subsequently censored from
survival analysis on the date of their new cancer diagnosis.
To identify patients who had been in contact with the Department
of Oncology or who had died, the national registry recording status
on all Danish citizens as to their contact to the healthcare system
and date of death was used. Patients with non-pathologically
verified recurrence and patients receiving adjuvant chemotherapy
were found by evaluating patient charts in the Departments of
Oncology. A search in the ‘Cause of Death Registry’ identified
patients registered with colon cancer as the cause of death. Follow-
up was closed at 1 January 2010. From the study population of 520
patients, we identified the following: 206 patients had died and 73
patients had experienced disease recurrence. According to the
registries, 90 patients had died from colon cancer, only 53 of these
patients were also identified as having disease recurrence and in
the analysis of recurrence-free cancer-specific survival (RF-CSS)
events on the remaining 20 patients were added giving 110 events.
The date registered was the first coming event of either disease
recurrence or death from colon cancer. We also identified
16 patients who had received adjuvant chemotherapy and 23
patients who had been diagnosed with another cancer.
Pathology
One FFPE tissue block representing the invasive front of the
tumour of each patient was collected from the Departments of
Pathology in Denmark. Information on T-category, malignancy
grade, nerve- and vascular-invasion, and the number of lymph
nodes assessed was obtained from the pathology reports. Patients
were scored as ‘not assessed’ if the pathological feature was not
described. Data on localisation, tumour perforation, and tumour
fixation was obtained from the DCCG registry and based on the
surgeons’ reports.
In situ hybridisation
In situ hybridisation was performed essentially as described
previously (Nielsen et al, 2011). In brief, the single 6-mm section
from each tumour was processed in a Tecan Evo (Ma¨nnedorf,
Switzerland) automated ISH instrument. Predigestion with protei-
nase-K (15mgml 1) was performed at 371C for 8min. After pre-
hybridisation for 15min in hybridisation buffer (Exiqon, Vedbaek,
Denmark), double-digoxigenin labelled 22’mer LNA probe specific
for full-length miR-21 (Exiqon) was incubated at 30 nM for 1 h at
591C. SSC stringent washes were performed at 591C. Probe was
detected with alkaline phosphatase-conjugated Fab fragments
diluted 1 : 800 (Roche, Mannheim, Germany), followed by 1 h
incubation with NBT-BCIP substrate (Roche). Sections were
dehydrated and mounted using Eukitt (VWR, Herlev, Denmark).
All reagents, including the proteinase-K, the DIG-labelled probe
and the anti-DIG antibody were from the same batch and prepared
identically each day. All steps in the Tecan were controlled
regarding volumes, temperature and time.
Image analysis
Quantification of relative expression levels was obtained essentially
as described earlier (Nielsen, 2012). In brief, the tumour area was
identified on overview images and digitally selected as a region of
interest. The areas containing normal mucosa and submucosa and
ulcerating areas were not included. Within the selected area, 25
random images were collected per slide using a  20 objective.
Exposure of sample images was strictly controlled and locked at
6.993ms with RGB (red–green–blue) values at 170–180 in non-
stained blank areas. Sample images with staining artifacts were
discarded, as were also images with o10% cancer cells in the
image field. Thus, all images contained both cancer cells and
stromal cells. A Bayesian pixel classifier to discriminate blue (B,
ISH signal), red (R, nuclear counter stain), purple (P, blue ISH
signal overlaying nuclear stain) and tissue background was
designed based on three images from three different tumours that
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represented variations in blue and red colour. The following
parameters were obtained for each sample image; B, R, P, total blue
(TB¼BþP), total red (TR¼RþP) and TBR¼TB/TR.
Series of 50 slides were analysed and included two control slides
in each series to obtain a precision estimate of the measurements.
The series also included replicates of adjacent sections
obtained from three tumours (CVo49%). The variation of TBR
between individuals was 215%, indicating that the precision of
the measurements was sufficiently high to justify statistical
analyses (25).
A test run, using four sections from each of 12 tumours was
performed to adjust the probe concentration and the hybridisation
temperature for optimal signal intensity.
Statistical analysis
Overall survival was defined as time from surgery until death from
any cause. Recurrence-free cancer-specific survival (RF-CSS) was
defined as the time from surgery until documented tumour
recurrence or death from colon cancer, death from other causes
was censored and also patients diagnosed with other malignancies
were censored from the date of their new cancer diagnosis.
Survival was estimated according to the Kaplan–Meier method,
and the log-rank test was used to test for differences among
groups. The Cox regression model was used to adjust for known
prognostic factors; Gender, age, T-category, malignancy grade,
localisation, perforation, fixation and number of lymph nodes
(dichotomized into above and under 12). The proportional hazard
assumption was tested for all variables used in the Cox model,
using Schoenfeld residuals. All statistical calculations were carried
out using the STATA 11.0 (StataCorp LP, College Station, TX,
USA), and all statistical tests were two-sided with a significance
level of 0.05.
By visual inspection of the relevant qq-plots, the
log-transformed miR-21 values (TB and TBR) followed normal
distributions.
RESULTS
Patient characteristics
Patient characteristics are presented in Table 1. The majority of the
patients were female patients with a medium differentiated T3
tumour. Location of the tumours was evenly distributed between
left (left flexure, descendent, sigmoid) and right colon (coecum,
ascendant, right flexure, transverse). Owing to the low number and
uncertainty of the low malignancy grade classification, tumours of
low and medium malignancy were pooled together in the survival
analysis. No significant associations were found between miR-21
expression and patient characteristics.
Localisation of miR-21 ISH signal
The miR-21 ISH signal intensity and prevalence varied consi-
derably within the tumours and between patients, and it was
predominantly seen in fibroblastic stromal cells (Figure 1C).
We found that miR-21 was predominantly expressed in fibroblast-
like cells in the stromal compartment of the tumour. In a smaller
fraction of the samples (10–20%) some miR-21-positive cancer
cells were also seen (Figure 1F), and in these cases only sub-
populations of cancer cells were miR-21 positive. The miR-21-
positive cancer cells also included budding cancer cells.
The intensity varied from patient to patient and locally
within the tumour slide. The miR-21 expression pattern was
characterised by intense expression in the tumour area in contrast
to the normal mucosa, where weakly stained mononuclear cells
were observed.
Quantification of miR-21 ISH signal
To quantify the ISH signal in the tissue sections, systematic
random non-overlapping image fields were compiled from each
tumour section. A mean of 16 image fields (range: 8–26) were
compiled from each tumour. If the number of image fields was less
than eight for one tumour section, the patient was excluded from
the statistical analyses. All image fields that passed the inclusion
criteria (see Patients and Methods) were processed with a pixel
classifier that discriminated the blue ISH signal (B), the red nuclear
stain (R), the blue signal located over red nuclear stain (P) and all
other tissue structures (see Figures 1C and F). Total blue area
(TB¼BþP), total red area (TR¼RþP) and total blue area per
total red area (TBR¼TB/TR) were obtained of which the TB and
TBR values represent estimates of miR-21 expression, and TR the
overall nuclear density. Sections cut too thin, samples fixed
inadequately and tumours with poor cell density (prevalent in
mucinous lesions) generally had low TR, and cases with TR
o20 000 mm2 were excluded, see patients paragraph. As expected,
substantial variation of both TB and TBR was observed; TB
range¼ 23.61–185 274 mm2; TBR range¼ 0.0001814–13.085, as
Table 1 Patient characteristics of the study population (all excluded
patients have been subtracted)
Parameter
Number of
patients
Study population 520
Gender
Male 231 (44.4%)
Female 289 (55.6%)
Age (years)
Median 71.9
Range 33–95
T-category
3 454 (87.3%)
4 66 (12.7%)
Malignancy grade
Low 34 (6.5%)
Medium 391 (75.2%)
High (including mucinous, signet) 95 (18.3%)
Localisationa
Right 269 (51.7%)
Left 251 (48.3%)
Tumour perforation 45 (8.7%)
Tumour fixation 93 (17.9%)
Lymph nodes
Median 11.3
Range 0–40
Nerve invasion
Yes 34 (6.5%)
No 360 (69.2%)
Not assessed 126 (24.2%)
Vascular invasion
Yes 30 (5.8%)
No 372 (71.5%)
Not assessed 118 (22.7%)
Information on T-category and malignancy grade was obtained from HE-stained
sections. Nerve and vascular invasion was obtained from the pathology reports and
was scored ‘not assessed’ when the histopathological feature was not described.
aLeft¼ left flexur, descendens, sigmoideum; right¼ coecum, ascendens, right flexur,
transversum.
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illustrated in Figure 2 where patients were divided into tertiles
according to their mean log(TBR) value.
The prognostic value of miR-21
Results from the log-rank analysis of mean log(TBR) are listed in
Table 2. Patients expressing high levels of miR-21 (high mean
log(TBR)) had significantly inferior RF-CSS (HR¼ 1.26; 95% CI:
1.15–1.60; Po0.001), and the same applied to mean log(TB)
(HR¼ 1.12; 95% CI: 1.0–1.42; P¼ 0.05). Proportional hazard
assumptions were tested for all variables. Results from the multiple
Cox regression are outlined in Table 3 and included age, gender,
T-category, malignancy grade, localisation, tumour perforation,
tumour fixation and number of lymph nodes. Mean log(TBR) was
found to be an independent predictive marker of poor RF-CSS
(HR¼ 1.41; 95% CI: 1.19–1.67; Po0.001), and the same applied to
high levels of mean log(TB) (P¼ 0.018). In addition to mean
log(TBR), the following parameters were found to be predictive of
a poor outcome regarding RF-CSS in the Cox regression analysis:
male gender (P¼ 0.033), T4-category (Po0.001), and tumour
perforation (Po0.001). In the Cox regression analysis of OS, the
following parameters were found to be prognostic of a poorer
outcome; increasing age (Po0.001), male gender (Po0.001) and
T4-category (P¼ 0.017). We did not find any significant relation
between miR-21 expression and OS.
Vascular and nerve invasion were not described in a large
fraction of the patients (22.7% and 24.2%, respectively). Thus, the
Cox regression analysis was only performed with respect to these
two pathological features in the limited subsets of patients.
However, high levels of mean log(TBR) was consistently found
Figure 1 Localisation and image analysis of miR-21 in situ hybridisation signal in colon cancer. Paraffin sections from two representative colon cancers
(A–C and D–F) stained for miR-21 using LNA-based in situ hybridisation. The images, A and D, are selected random images obtained with a  20
objective. A selected area in A and D has been enlarged in B and E, and is presented after colour segmentation in C and F. The miR-21 in situ hybridisation
signal (blue, examples indicated by arrows in B and C) is seen in tumour-associated stromal fibroblast-like cells (B, arrows) in virtually all colon tumours,
whereas miR-21 signal in cancer cells (E, arrows) was less frequently seen. For quantitation of the in situ hybridisation signal, the blue and purple stain in A/B
and D/E are translated into green and yellow pixels in C and F. The nuclear red counterstain is likewise translated into red and the tissue background into
black in C and F. Bars are 50 mm.
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Figure 2 Box-plot of miR-21 expression levels in patients divided into
tertiles of log(TBR). Substantial variation of both TB and TBR was observed;
TB range¼ 23.61–185 274 mm2; TBR range¼ 0.0001814–13.085.
Table 2 Log-rank test on OS and RF-CSS related to log-transformed
mean values of log(TBR)
OS RF-CSS
Hazard ratio
(95% CI) P-value
Hazard ratio
(95% CI) P-value
Mean log(TBR) 1.05 (0.94–1.18) 0.38 1.26 (1.15–1.60) o0.001
Abbreviations: OS¼ overall survival; RF-CSS¼ recurrence-free cancer-specific survival.
P value o0.001 is indicated in bold.
Table 3 Cox regression analysis on OS and RF-CSS related to log-
transformed mean log(TBR), including gender, T-category, malignancy
grade, localisation, tumour perforation, tumour fixation and number of
lymph nodes
OS RF-CSS
Hazard ratio
(95% CI) P-value
Hazard ratio
(95% CI) P-value
Mean log(TBR) 1.08 (0.97–1.22) 0.17 1.41 (1.19–1.67) o0.001
Age 1.06 (1.04–1.07) o0.001 1.02 (1.00–1.04) 0.055
Male gender 1.81 (1.36–2.42) o0.001 1.54 (1.04–2.29) 0.033
T4-category 1.59 (1.09–2.32) 0.017 2.51 (1.58–3.97) o0.001
Left localisation 0.93 (0.70–1.25) 0.64 1.04 (0.69–1.55) 0.87
Perforation 1.57 (0.99–2.49) 0.056 2.69 (1.56–4.63) o0.001
Fixation 1.41 (0.98–2.04) 0.064 1.41 (0.86–2.32) 0.17
Lymph nodes X12 1.03 (0.78–1.37) 0.84 0.93 (0.64–1.38) 0.74
High malignancy grade 1.24 (0.87–1.77) 0.24 1.54 (0.95–2.50) 0.08
Abbreviations: CI¼ confidence interval; OS¼ overall survival; RF-CSS¼ recurrence-
free cancer-specific survival. P values o0.001 are indicated in bold.
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to be significantly related to poor RF-CSS (HR¼ 1.52; 95% CI:
1.23–1.88; Po0.001). The same applied to log(TB) (P¼ 0.008).
To illustrate the effect of increasing mean log(TBR), the
population cohort was stratified into tertiles according to their
mean log(TBR) value. As illustrated in Figure 3, patients with mean
log(TBR) values in the upper tertile had significantly shorter RF-
CSS (HR¼ 1.92; 95% CI: 1.19–3.09; P¼ 0.008) compared with
patients with mean log(TBR) values in the lower tertile.
DISCUSSION
At present, the decision on adjuvant chemotherapy for stage II
colon cancer patients is based on clinical and pathological markers
of risk, which are inadequately informative in most of the patients,
and better methods are certainly needed (Tournigand and de
Gramont, 2011). For several years, new prognostic markers of
significant importance have been a central topic in cancer research
with the perspective of individualised treatment.
Most studies have been retrospective and included small
numbers of highly selected patients. The risk of such studies being
false positive is very high, and it has become evident that most
biomarker studies have failed verification in new independent
patient series (Locker et al, 2006). However, the present study
included nearly all stage II patients in a population of 5 million
people and can thus be considered unbiased with regard to selection.
The present study shows that increasing mean log(TB)
(representing the relative miR-21 expression level) and mean
log(TBR) (representing values normalised to the nuclear density)
are significantly related to decreasing RF-CSS. These results thus
confirm the prognostic importance of miR-21 independently from
prognostic markers, proven to be inadequate, for example,
T-category, malignancy grade, tumour perforation, tumour fixa-
tion, invasion of nerves and invasion of veins. Our results are in
agreement with the previous study by Nielsen et al (2011)
reporting that high miR-21 levels determined by ISH in 130 cases
of stage II colon cancer is correlated with poor disease-free
survival. The findings were based on a sample cohort as part of the
RANX study and contained patient samples collected from 1991 to
1993 (Nielsen et al, 2011). They also found a significant impact on
OS. In contrast, we found no prognostic value of miR-21 in
analyses of OS. At the cut-off point set to 1 January 2010, 116
patients had died from other causes than colon cancer, whereas
110 patients had experienced relapse or had died from colon
cancer. This indicates that at least half of stage II colon cancer
patients die from causes other than colon cancer. Hence, OS
analyses will be diluted, calling for endpoint analyses focusing on
recurrence of the disease.
Our results are also in keeping with previous studies using PCR
to quantify miR-21 in CRC tissue. Schetter et al (2008) studied the
profile of the miRNA expression in paired tumour and normal
tissue samples from 84 patients with colon cancer (29 stage II
patients) as a training set and paired samples from another 113
patients with colon cancer (37 stage II patients) as a validation set.
Among the 37 miRNAs that were differentially expressed, miR-21
was selected for validation. They found that high expression of
miR-21 was significantly associated with poor prognosis, independent
of T-category, age, sex and tumour location (Schetter et al, 2008).
Slaby et al (2007) also reported that miR-21 upregulation in CRC
patients was associated with lymph node positivity and development
of distant metastasis based on their study of 29 patients.
In this study, the majority of tumours expressed the miR-21 ISH
signal in fibroblast-like stromal cells. However, miR-21-positive
cancer cells were also found in a small fraction of the tumours.
Previous studies using identical probes to visualise miR-21 report
the same distribution (Nielsen et al, 2011; Rask et al, 2011), while
other groups using different probes describe miR-21-positive
tumour cells in the majority of the tumours (Schetter et al, 2008;
Yamamichi et al, 2009). The reason for the discrepancies could be
explained by cross-reaction of the probe to ‘similar sequences’
allowed under suboptimal hybridisation conditions as well as
different reagents employed to detect the labelled probe. However,
it can not be excluded that a different probe could influence the
results. It is noteworthy that miR-21 demonstrates prognostic
impact despite the fact that it is found in the stroma cells and not
in the tumour cells. Explanations are speculative but it can not be
excluded that signals from stroma to the tumour cells, including
paracrine signalling, influence the behaviour of the tumour.
Because of the exclusion criterion that each slide should be
evaluated by at least eight images, 41 patients were excluded. This is
most likely explained by the fact that we collected the tumour block
representing the invasive front from each patient. Therefore, some of
the blocks had small tumour content and as the software did not allow
image fields to overlap, fewer images were available for analysis.
Using image quantified ISH we were able to assess miR-21 on
archival FFPE tissue in this unique population. The results showed
that increasing mean log(TBR) is an independent prognostic
marker of poor RF-CSS in a stage II colon cancer population
consisting of nearly all patients diagnosed with this disease in
Denmark in the year 2003. Our findings strongly suggest that miR-
21 measured by ISH is a robust and valuable indicator of adverse
prognosis in stage II colon cancer. The results call for evaluation
together with other variables to generate a fully specified
prognostic index, pointing out the individuals, in this group of
patients, in need of adjuvant chemotherapy. Eventually, such an
index should be tested in a prospective, randomised trial setting
for conclusive evaluation of the clinical impact.
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